<DOC>
	<DOCNO>NCT00299104</DOCNO>
	<brief_summary>This phase III , randomize , control , double-blind , parallel group , international study approximately 750 patient active Rheumatoid Arthritis ( RA ) naive Methotrexate ( MTX ) therapy . Rheumatoid Factor ( RF ) -positive RF-negative patient enrol allocate equally 3 treatment arm .</brief_summary>
	<brief_title>A Study Evaluate Rituximab Combination With Methotrexate Methotrexate-Naive Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Adult patient 1880 year age RA â‰¥ 2 month ; Receiving outpatient treatment Patients naive , consider candidate , methotrexate treatment Exclusion criterion : Rheumatic autoimmune disease RA , significant systemic involvement secondary RA Inflammatory joint disease RA , systemic autoimmune disorder Diagnosis juvenile rheumatoid arthritis , RA age 16 Surgery within 12 week study Previous treatment approve investigational biologic agent RA , antialpha4integrin antibody costimulation modulator , celldepleting therapy Concurrent treatment biologic agent DMARD methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>MTX</keyword>
	<keyword>RA</keyword>
	<keyword>IMAGE</keyword>
	<keyword>WA17047</keyword>
</DOC>